Fetal safety profile of aromatase inhibitors: Animal data

Gian Mario Tiboni1, Adalisa Ponzano1

  • 1Department of Medicine and Aging Sciences, University "G. d'Annunzio" of Chieti-Pescara, Italy.

Insights

Aromatase inhibitors (AIs) can harm prenatal development, even at low doses. Exposure during pregnancy, from early stages to fetal periods, may cause embryo/fetal death and developmental abnormalities.

Area of Science:

  • Reproductive toxicology
  • Developmental biology
  • Endocrinology

Background:

  • Aromatase inhibitors (AIs) reduce estrogen production from androgens.
  • Estrogens play crucial roles in development.
  • Understanding AI developmental toxicity is vital for risk assessment.

Purpose of the Study:

  • To review the prenatal developmental toxicity of AIs.
  • To identify vulnerable developmental windows and potential adverse effects.

Main Methods:

  • Review of experimental studies on AI prenatal exposure.
  • Analysis of effects across different gestational stages in animal models.

Main Results:

  • AIs can impact pregnancy at therapeutic or lower doses.
  • Vulnerability extends from preimplantation to fetal periods.
  • Key effects include reduced embryo/fetal survival, skeletal and morphological anomalies, and placental enlargement.

Conclusions:

  • Prenatal exposure to AIs during a broad gestational window can significantly impair development.
  • Findings highlight the need for caution regarding AI use during pregnancy.